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Cellular metabolic needs are fulfilled by transport of amino acids
across the plasma membrane by means of specialized transporter
proteins. Although many of the classical amino acid transporters
have been characterized functionally, less than half of these
proteins have been cloned. In this report, we identify and charac-
terize a cDNA encoding a plasma membrane amino acid trans-
porter. The deduced amino acid sequence is 505 residues and is
highly hydrophobic with the likely predicted structure of 9 trans-
membrane domains, which putatively place the amino terminus in
the cytoplasm and the carboxy terminus on the cell surface.
Expression of the cRNA in Xenopus laevis oocytes revealed strong
transport activities specific for histidine and glutamine. This pro-
tein is a Na1- and pH-dependent transporter and tolerates substi-
tution of Na1 by Li1. Furthermore, this transporter is not an
obligatory exchanger because efflux occurs in the absence of
influx. This transporter is expressed predominantly in the liver,
although it is also present in the kidney, brain, and heart. In the
liver, it is located in the plasma membrane of hepatocytes, and the
strongest expression was detected in those adjacent to the central
vein, gradually decreasing towards the portal tract. Because this
protein displays functional similarities to the N-system amino acid
transport, we have termed it mNAT, for murine N-system amino
acid transporter. This is the first transporter gene identified within
the N-system, one of the major amino acid transport systems in the
body. The expression pattern displayed by mNAT suggests a
potential role in hepatocyte physiology.
Amino acid transport across the plasma membrane intro-duces essential nutrients into cells, providing critical sub-
strates for protein biosynthesis, hormone metabolism, regulation
of cell growth, and production of metabolic energy, to name a
few (1). Defective amino acid transport systems and the candi-
date transporter genes are known to be involved in several
diseases (2). For example, the dicarboxylic amino aciduria
developed by the null knockout EAAT3 mice revealed the
putative role of an anionic amino acid transporter in this
inherited disease (3). The pioneer work on amino acid transport
was documented approximately three decades ago; however,
more recently based on substrate specificity and sodium depen-
dence, a classification of several systems was reached (4). In
1990, the first amino acid transporter gene for GABA was
identified (5) and served as the starting point for the cloning of
other mammalian amino acid transporter genes. The genes
identified so far correspond to eight classical transport systems;
whereas the genes encoding the remaining eight of the major
amino acid transport systems are unknown (6).
Although the transporters identified thus far have multiple
transmembrane domains and display some degree of substrate
overlap, they share little sequence homology. The lack of
high-affinity inhibitors, resistance to expressional cloning espe-
cially for nonneural amino acid transporters, as well as the fact
that the transporters are expressed in low abundance in the
plasma membrane complicates their structural identification and
isolation. Thus, progress towards the molecular identification of
amino acid transporters across the various systems has pro-
ceeded very slowly. In this report, we have identified a plasma
membrane amino acid transporter gene with nine predicted
transmembrane domains. This protein has no sequence homol-
ogy with other mammalian amino acid transporter families
expressed in the plasma membrane, but shares less than 20%
homology with the vesicular g-aminobutyric acid (GABA) trans-
porter (6, 7). This protein preferentially transports histidine and
glutamine, and possesses other functional features, which are
similar to N-system amino acid transport. Thus we propose to
name it mNAT (for N-system amino acid transporter). N-system
amino acid transport is known to have an important role in
glutamine uptake for the urea cycle (8) and export of newly
synthesized glutamine for glutamine metabolism in the liver (9,
10). These transporting activities could be efficiently blocked by
histidine (11). In addition, N-system transport is identified in the
brain, where it appears to have a functional role in the blood–
brain barrier (12, 13). Interestingly, mNAT is also abundantly
expressed in liver and brain. In the liver, it is localized in the
plasma membrane of hepatocytes surrounding the central vein
and the levels of expression gradually decrease towards portal
tract, suggesting a potential physiological function of this trans-
porter in this organ.
Materials and Methods
Isolation of mNAT cDNA Clones. Originally, we attempted to use a
mouse genomic library to screen for unknown gap junction
proteins, connexins (Cx). The mouse genomic library was con-
structed by using the GenomeWalker Kit (CLONTECH; K1805-
1). The genomic DNA was isolated from a mouse cell line,
MC3T3-E1. Two degenerate primers were designed based on the
known connexin coding sequences (Cx43, Cx45, and Cx46),
sense primer: GGTyC TGTyC, AyGACyAyG AACyT GTCyT
TGCyT TACyT GACyT; antisense primer: CTC CyAGT
CyGGG GyAyCCTG TyGGA AyGyCAGyTyC GTyAA CyGy
ACA. After PCR amplification of over 30 cycles with annealing
temperatures of 40°C, we obtained several fragments. In addi-
tion to fragments encoding connexins, a fragment of 0.6 kb was
obtained. To determine the full-length cDNA of this gene, a
preliminary Northern blot analysis was performed using this
fragment as a probe: a 2.4-kb transcript in mouse kidney, liver,
brain, and heart. To obtain the cDNA sequence, polyadenylated
RNA was isolated from mouse kidney using a mRNA Separator
Kit (CLONTECH). mRNA was converted to double-stranded
cDNA using the Two-Hybrid cDNA Library Construction Kit
(CLONTECH). The cDNA fraction between 2.0 and 2.5 kb was
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isolated using a 1.5% agarose gel, purified with a Gel Extraction
kit (Qiagen, Santa Clarita, CA) and then subcloned into vector
pGAD10 (CLONTECH). PCR-based screening was performed
using the primer pairs: sense 59-AATTCGCGGCCGCGTC-
GAC (linker primer), and antisense 59-GCTGTAAGCAG-
GAACAGGAAAAGGATGAT (corresponding to nucleotides
426–398 of mNAT). To obtain the full-length transcript, 59-rapid
amplification of cDNA ends (RACE) was performed with the
Marathon cDNA amplification Kit (CLONTECH) according to
the instructions from the manufacturer. Primers 59-
GCTAGGGGCAGAATGATGGTGACAG (nucleotides 725–
702) and 59-CATGATGGCGTTGCTGAGAT (nucleotides
352–333) were used as gene-specific primers for the first and
nested PCR of 59-RACE, respectively. Each DNA fragment was
sequenced automatically on both strands with specific oligonu-
cleotide primers (sequenced in the UTHSCSA DNA Sequencing
Facility). To ensure that the sequence of mNAT obtained from
kidney was exactly the same as that expressed in other tissues,
reverse transcription (RT)-PCR and sequencing were per-
formed using RNA isolated from brain and liver (1 mg) as
previous described (14).
Northern Blot Analysis. Northern blots were performed as de-
scribed (14). Briefly, total RNA was isolated from mouse tissues
(liver, brain, kidney, lung, heart, small intestine, muscle, and
testis) using TRI REAGENT (Molecular Research Center,
Cincinnati). Equal amounts of RNA were loaded and separated
on a 1% agarose gel in the presence of formaldehyde, and
transferred to a nylon membrane (Oncogene). The membrane
was hybridized at 45°C in 50% formamide with a [32P]dCTP-
labeled 602 bp of PCR fragment corresponding to nucleotides
1,135–1,737 of mNAT. The probed membrane was washed at
65°C in 0.13 SSC and 0.1% SDS.
Expression of mNAT and Human g17 in Xenopus laevis Oocytes. To
prepare mRNA for oocyte injection, cDNAs were synthesized by
PCR and subcloned between the 59- and 39-f lanking sequences
of Xenopus b globin gene previously described (15). The primer
pairs used to amplify the full ORF from mNAT and human g17
were designed with a restriction site BamHI at 59 end and
HindIII at 39 end. Primer pairs for mNAT consist of a sense
59-AATGGATCCATGGAGATACCCCGACAGACA and an
antisense primer 59-ATCGAAGCTTAGGTCATCCTAATG-
GTTTC. Primer pairs for human g17 included a sense 59-
AATGGATCCATGGAGGCGCCTTTGCAGACA and an an-
tisense primer 59-ATCGAAGCTTAGGTCATCCTAGTG-
GTTTC. PCR products were gel-purified with the Gel
Extraction kit (Qiagen) and digested with BamHI and HindIII,
before subcloning into the Xenopus expression vector. The
constructs were verified by sequencing.
The plasmids were linearized with NotI, and in vitro transcrip-
tion reactions by T7 RNA polymerase were performed with
mMESSAGE mMACHINE (Ambion, Austin, TX). Capped
cRNAs were extracted with phenolyCHCl3, precipitated with
ethanol as described previously (15), resuspended in DEPC-H2O
at a concentration of 1.5–2.0 mgyml and stored in aliquots of 3 ml
at 280°C before use.
Antibody Preparation. Rabbit anti-mNAT IgG antibody was pro-
duced using a glutathione S-transferase (GST) tagged fusion
protein as described previously (14). A DNA fragment encoding
amino acids 1–79 was produced by PCR using a full-length
mNAT as a template (sense primer: 59-AATGGATCCATG-
GAGATACCCCGACAGACA, anti-sense primer: 59-AG-
GAATTCATGATGGCGTTGCTGAGAT) and inserted into
the expression pGEX-2T vector (21). The recombinant fusion
protein was expressed in Escherichia coli induced by isopropyl-
thio-b-D-galactoside and isolated with GST-beads (Sigma). The
purified protein was used to raise a rabbit polyclonal antiserum
(Pocono Rabbit Farm, Canadensis, PA). The antisera generated
were affinity-purified by passage through two Sepharose CL-4B
columns, GST-conjugated and GST-mNAT fusion protein con-
jugated, respectively.
Membrane Protein Preparation, Western Blot, Glycosylation, and
Phosphorylation Analyses. Crude membrane extracts including
plasma and intracellular membrane proteins were prepared from
Xenopus oocytes and mouse tissues as previous described (14,
16). Briefly, tissues and cells were homogenized in lysis-buffer
(Tris 20 mM, NaCl 100 mM, PMSF 20 mM, and leupeptin 10
mgyml). The homogenate was centrifuged at 10,000 3 g at 4°C
for 10 min to discard yolk and cellular debris. The supernatant
was centrifuged at 100,000 3 g at 4°C for 30 min. The membrane
pellet was resuspended in lysis buffer containing 1% SDS and
1% b-mercaptoethanol. The protein concentration was deter-
mined using a microBCA assay (Pierce). One microgram of
protein was loaded on a 10% SDSyPAGE and transferred to a
nitrocellulose membrane. The membrane was probed with a
1:500 dilution of affinity-purified preimmune and anti-mNAT
IgG. The primary antibody was detected using peroxidase-
conjugated secondary anti-rabbit antiserum and followed by
chemiluminlunance reagent kit (ECL) (Amersham Pharmacia)
according to the manufacturer’s instruction. The membranes
were exposed to X-Omat AR films (Eastman Kodak, Rochester,
NY) and detected by fluorography. To analyze the specificity of
mNAT antibody toward the mNAT antigen, the mNAT fusion
protein (0.2 mgyml, 2 mgyml, and 20 mgyml) was preincubated
with mNAT antibody (1:400) or Cx43 antibody (1:400), and
Western blots were performed with the preabsorbed antibody.
The deglycosylation experiments were performed using a
Glycoprotein Deglycosylation Kit (Calbiochem) strictly follow-
ing the manufacturer’s instructions. The deglycosylation enzymes
contained in the kit include N-glycosidase F, Endo-a-N-
acetylgalactosaminidase, a2,3,6,8-neuraminidase, b1,4-galactosi-
dase and b-N-acetylglucosaminidase. The dephosphorylation assay
was performed as previously described (14).
Transport Assays. Stage V-VI oocytes from Xenopus laevis were
dissected and injected with 50 nl of the synthetic mRNA or
DEPC-H2O as control. After 3 days of incubation at 18°C,
functional analyses were performed in groups of 5–10 oocytes
per assay as described previously (17–19). Oocytes were rinsed
briefly in uptake buffer (KCl, 2 mM; MgCl2, 1 mM; CaCl2, 1 mM;
Hepes, 10 mM; and Tris, 50 mM) in the presence of 100 mM
NaCl (Na1-buffer), 100 mM choline chloride (choline1-buffer),
or 100 mM LiCl (Li1-buffer). These oocytes were transferred
into a 24-well culture dish containing 2 ml uptake buffer and
were incubated for 2–60 min at room temperature. Amino acid
transport activities were measured by incubating oocytes in 0.5
ml of uptake buffer in the presence of 50 mM L-amino acids plus
corresponding [3H]-labeled L-amino acids (New Life Science,
Boston, MA) as tracers for 15 or 30 min. The oocytes were
washed four times in uptake buffer. These oocytes were lysed in
100 ml of 2% SDS, and the radioactivity accumulated by each
oocyte was measured with a scintillation counter (Beckman
Coulter) in 5 ml of scintillation solution. The specificity of
mNAT-mediated amino acid uptake was examined using an
amino acid competition assay. L-histidine uptake (50 mM) was
measured in the presence of 5 mM nonradioactive amino acid.
The Na1-dependence and Li1-tolerance of histidine transport by
mNAT were investigated using choline1-buffer or Li1-buffer
instead of Na1-buffer. The effects of extracellular pH on L-
histidine and L-glutamine uptake mediated by mNAT was in-
vestigated at pH 6–8.5 by adjusting Na1-buffer with Tris-base or
hydrochloric acid as described (18, 19). L-histidine efflux was
measured as previously described (20). Briefly, injected oocytes
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were incubated for 30 min in Na1-buffer containing 50 mM [3H]
L-histidine. After washing in Na1-buffer containing 50 mM
nonradioactive L-histidine, oocytes were transferred to 300 ml
Na1-buffer or Na1-buffer containing 1 mM nonradioactive
L-histidine. Samples (2 ml) were taken at the designated times to
determine the levels of radioactivity. All experiments were
repeated at least three times, and the data collected were
presented as SEMs.
Immunofluorescence and Confocal Laser Microscopy. The immuno-
fluorescence detection of mNAT was performed as described
previously (22). Briefly, oocytes and tissue samples were fixed in
2% paraformaldehyde for 2 h at 4°C, washed three times with
PBS, incubated in 30% sucrose in PBS overnight at 4°C, em-
bedded in OCT (Miles Scientific), and then frozen in liquid
nitrogen. Frozen tissue sections (5–10 mm) were incubated with
blocking solution (2% normal goat serum, 2% fish skin gelatin,
and 1% BSA in PBS) for 30 min and then with affinity-purified
anti-mNAT (1:500 dilution in blocking solution) at room tem-
perature for 2 h. The primary antibodies were detected by
fluorescein (FITC)-conjugated goat anti-rabbit Ig for 2 h at
room temperature. The specimens were analyzed with either an
upright fluorescence microscope (Olympus Optical, Tokyo, Ja-
pan) or a confocal laser scanning microscopy (Model: Fluoview,
Olympus). FITC fluorescence was excited by a 488-nm argon
laser light.
Results and Discussion
Screening a mouse genomic DNA library resulted in the isolation
of a 0.6-kb DNA fragment, of which, 110 bp shared partial
homology with members of transporter families present in
databases [BLAST, National Center for Biotechnology Informa-
tion (NCBI) file servers] (23), which include human transporter
protein (g17) mRNA (U49082), amino acid transporter in
arabidopsis (U397820), amino acid permease 1 in Nicotiana
sylvestris (U31932), and transposase in Pseudomonas stutzeri
(AF039534). Northern blot analysis using this fragment as a
probe revealed a ’2.4-kb transcript in mouse kidney. A PCR-
based cloning strategy using a mouse kidney cDNA library
yielded a 2,412-bp cDNA encoding a 505-amino acid protein
with a predicted molecular mass of 56 kDa. The ORF is flanked
by 115 nucleotides of 59-untranslated region (UTR), 842 nucle-
otides of 39-UTR, a long poly(A) tail, and a variant polyadenyl-
ation site (TATAAA) between nucleotides 2,394 and 2,400.
Comparison of this sequence at the nucleotide and amino acid
levels with known databases (BLASTN, BLASTP, and BLASTX,
NCBI file servers) led to the identification of a single sequence,
which was 89% homologous at the amino acid and 84% homol-
ogous at the nucleotide coding region with human g17 (a
putative transporter, GDB g:1840044). Although this protein has
no sequence homology with any identified mammalian plasma
membrane amino acid transporters, homologies of less than 25%
were found with 51 other transmembrane proteins. Twenty-one
of them are related to amino acid transporters from plants, yeast,
and worms, and two are vesicular GABA transporters from rat
(AF030253) and mouse (AJ001598). The alignment of amino
acid sequences of mNAT and human g17 is shown in Fig. 1a, in
which most of the predicted transmembrane domains are con-
served (TM1–TM9). Hydrophobicity studies predict that mNAT
is a plasma membrane protein (certainty 5 0.60, PSORT version
Fig. 1. Amino acid sequence and molecular structure of mNAT. (a) The
deduced amino acid sequence of mNAT in one-letter code is aligned to the
human g17 using the BLAST 2 software (33). Identical residues are shaded in
gray. Putative membrane-spanning domains are numbered and doubly un-
derlined. (b) Transmembrane topology of mNAT as predicted from hydropho-
bicity plots determined with programs obtained from EMBNET, PSORT, and BCM
Search Launcher servers. (c) Hypothetical membrane topology model of mNAT
is based on its hydropathy profile.
Fig. 2. Expression of mNAT in Xenopus oocytes. (a) Frozen sections of
Xenopus laevis oocytes 3 days after injection with cRNA of mNAT were labeled
with anti-mNAT antibody or preimmune serum and were examined by con-
focal microscopy at a scanning interval section of 0.5 mm. (Bar, 30 mm.) (b)
Western blot analysis demonstrates overexpression of mNAT (arrrowhead)
using a specific antibody in extracts from oocytes injected with water (lane 1),
mNAT cRNA (lane 2), or uninjected oocytes (lane 3).
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6, Nakai file server) with a higher probability of having 9
transmembrane domains (Swiss, EMBNET; PSORT and BCM Search
Launcher) as opposed to having 10 (Swiss, EMBNET). The
N-terminal segment is predicted to be in the cytoplasm and the
C-terminal tail facing the extracellular side (higher probability
score, PSORT version 6, Nakai file server) (Fig. 1 b and c). The
predicted molecular structure of mNAT with 9 transmembrane
domains is different from other known amino acid transporters,
which are composed of 10–14 transmembrane domains (6,
24–26). Together, these results suggest that this protein belongs
to a new family of amino acid transporters in mammalian cells.
To examine whether mNAT is a novel amino acid transporter,
the expression and function of mNAT was primarily investigated
in Xenopus oocytes (17, 18). Expression of mNAT was detected
by Western blot analysis and confocal immunofluorescence as
early as 24 h following cRNA injection. mNAT expression was
localized to the oocyte plasma membrane (at the limit of
resolution imparted by fluorescence microscopy) as detected by
an mNAT-specific antibody, whereas fluorescence levels were
undetectable with preimmune serum (Fig. 2a). A protein band,
’54 kDa was detected by Western blotting with a mNAT specific
antibody, which was undetectable in control oocytes (Fig. 2b).
Differences in the pattern of migration of mNAT were not
altered by deglycosylation or dephosphorylation treatments
(data not shown), indicating that the protein might not be
glycosylated nor may support phosphorylation.
The uptake of [3H]-labeled L-alanine (zwitterionic), L-
glutamate (anionic), and L-lysine (cationic) was measured in
Xenopus oocytes injected with mNAT cRNA. Compared with
controls, we found that mNAT expression induced a 10-fold
increase in the uptake of L-alanine (17.2 6 3.2 vs. 1.9 6 0.48,
measured in pmoly30 min per oocyte), 1.1-fold for lysine (69.9 6
4.7 vs. 63.8 6 3.0), whereas there was no significant transport of
glutamate (0.55 6 0.37 vs. 0.32 6 0.30). These results suggest that
mNAT is capable of transporting L-alanine across the plasma
membrane. To determine the substrate selectivity of mNAT, a
competition assay in the presence of all 20 amino acids was
performed. In this assay, the rate of uptake of L-alanine was
determined in oocytes injected with mNAT cRNA in the pres-
ence of nonradioactive-labeled amino acids. The uptake was
significantly inhibited up to an efficiency of 90% by L-histidine.
L-asparagine and L-glutamine showed a modest degree of inhi-
bition of L-alanine uptake (data not shown). Therefore, L-
histidine was selected as a model for amino acid competition
assay to examine the transport specificity of mNAT (Fig. 3a).
L-histidine uptake was significantly inhibited by L-histidine and
L-glutamine, suggesting that mNAT is an amino acid transporter
with greatest specificity for these two amino acids. To distinguish
between the known classical amino acid transport systems, we
examined the Na1-dependence and tolerance for substitution by
Li1. In the presence of Na1 buffer, L-histidine uptake into
oocytes injected with mNAT cRNA was significantly greater
Fig. 3. Functional characterization of mNAT expressed in Xenopus laevis oocytes. (a) Inhibition of 50 mM L-histidine uptake in oocytes injected with cRNA of
mNAT by 5 mM of 20 types of L-amino acids. The percentage values after subtracting controls injected with water are presented as 50 mM L-histidine uptake is
defined as 100%. *Bar represents L-histidine uptake in the absence of nonlabeled amino acids. (b) Uptake of 50 mM [3H]histidine was measured using
choline1-buffer or Li1-buffer to replace Na1-buffer. (c) pH dependence of L-histidine and L-glutamine uptake. Uptake of 50 mM [3H] L-histidine or L-glutamine
was measured with Na1-buffer under indicated pH. (d) Concentration dependence of L-histidine uptake by mNAT. Net uptakes of L-histidine and glutamine were
measured at different concentrations (0–10 mM) of L-histidine in Na1-buffer at pH 7.5. Km 5 1.1 mM and Vmax 5 170 pmolyminyoocyte for histidine, and Km 5
1. 55 mM and Vmax5 165 pmolyminyoocyte for glutamine were determined. (e) L-histidine efflux was examined in Na1-buffer and in Na1-buffer containing 2 mM
nonradioactive labeled-L-histidine. ( f) Uptake rates for L-alanine, L-glutamine, L-glutamate, L-histidine, and L-lysine were determined for oocytes expressing
mNAT and human g17.
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(23.8-fold higher) than that exhibited by control oocytes injected
with water. Choline ion substitution for Na1 led to a significant
decrease in L-histidine uptake, (6.8-fold lower) when compared
with that in Na1-buffer. Replacement of Li1 for Na1 did not
affect the rate of uptake of L-histidine (Fig 3b). These results
demonstrate that L-histidine uptake mediated by mNAT is
Na1-dependent and tolerant of replacement of Na1 by Li1.
Together, these features are consistent with an N-system amino
acid transporter as previously described (17, 27).
Since the N-system of amino acid transporters are known to
have a pH dependence (19), we tested whether extracellular pH
in the range between 6 and 8.5 had an effect on L-histidine and
L-glutamine uptake mediated by mNAT. The results revealed
that uptake of these two amino acids exhibited a similar pH-
dependency increasing from low to high pH (Fig 3c), confirming
that mNAT is a member of the N-system amino acid transporter
family. Furthermore, we investigated the concentration depen-
dence of L-histidine and L-glutamine uptake mediated by
mNAT. At concentrations between 0 and 1 mM, the rate of
uptake was an incremental function of concentration, whereas at
higher amino acid concentrations (5–10 mM), uptake was sat-
urated (Fig 3d). This observation indicated that L-histidine and
L-glutamine uptake in oocytes expressing mNAT exhibited the
characteristics of a carrier-mediated transport. Furthermore, to
determine whether the substrate affects eff lux of L-histidine,
eff lux of [3H] L-histidine was measured in mNAT overexpressing
oocytes, which were prelabeled with [3H] L-histidine and incu-
bated in Na1-buffer in the presence or absence of nonradioactive
L-histidine. Interestingly, in the presence of external L-histidine,
oocytes expressing mNAT showed significantly increased efflux
of [3H] L-histidine at later time points, as compared with control
oocytes incubated in the absence of external L-histidine (Fig 3e).
The explanation of this phenomenon could be that the uptake of
unlabeled histidine prevents depletion of intracellular substrate
stores, prolonging the activity of the transporter.
To elucidate the tissue-specific expression of mNAT, high-
stringency Northern blots of equivalent amounts of RNA iso-
lated from various tissues were probed with a mNAT DNA
fragment labeled with [32P]dCTP. A full-length transcript of 2.4
kb was detected in abundance in mouse liver, moderately
detected in kidney and brain, and barely detected in heart and
muscle (Fig. 4). The transcript from liver was observed even
when a 10-fold lower amount of RNA was loaded (see Fig. 4).
This finding is consistent with the restrictive localization of the
N-system amino acid transporters to the liver (6). Western blot
analysis with an mNAT-specific antibody on crude membrane
fractions isolated from liver, kidney, and testis revealed two
immunoreactive protein bands of Mr 67 and 54 kDaa in the liver
(Fig 5a, lane 2). The 67 kDa band, which is different from the
predicted molecular mass (56 kDa) of mNAT was also detected
in kidney (lane 1). There was no detectable mNAT expression in
testis (lane 3). The specificity of the two protein bands was
ascertained by the lack of detected immunoreactivity by probing
with preimmune serum (lane 4) or by preincubating the mNAT
antibody with the mNAT antigen (lane 5). Furthermore, an
antibody for the nonrelated protein, connexin 43, was not
competed off by the mNAT antigen (data not shown). The
differences between the expected and observed protein bands
could be caused by posttranslational modifications such as
glycosylation or phosphorylation. However, deglycosylation or
dephosphorylation treatment did not alter the mNAT migrating
patterns (data not shown), suggesting that it is unlikely that both
types of modifications can account for these differences. The
discrepancy between predicted and measured molecular weight
on SDSyPAGE and between the different migration patterns of
mNAT expressed in the oocyte, and in liverykidney, could be
caused by the structural complexity of membrane proteins. The
Fig. 4. Northern blot analyses of tissue-specific expression patterns of mNAT.
Northern blots with equal amount of total RNAs from different mouse tissues
were hybridized with a DNA probe of mNAT under high-stringency condi-
tions. The position of known size standards is shown on the left.
Fig. 5. Expression of mNAT in vivo. Immunoblot detection of mNAT expres-
sion in mouse liver, kidney, and testis (a). Crude membranes isolated from
kidney (lane 1), liver (lanes 2, 4, and 5), and testis (lane 3) were treated with
affinity-purified antibodies (1:400); anti-mNAT (lanes 1–3), preimmune (lane
4), and anti-mNAT pretreated with mNAT antigen (0.2 mgyml) (lane 5). Im-
munofluorescence detection localized mNAT to the plasma membrane of
hepatocytes that surround the central vein (V) (b). The expression diminishes
gradually toward portal tract (T) (c). The confocal laser fluorescence of 0.5-mm
interval section (d, phase; e, fluorescence) showed the expression of mNAT on
hepatocyte membrane, but not in endothelial cells (arrow). [(b) Bar, 20 mm; (c)
Bar, 200 mm; (d and e), Bar, 10 mm.]
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migration on SDSyPAGE is known to differ from predicted
levels in other proteins with multiple transmembrane segments,
such as gap junction proteins and connexin 56 (14, 28). The
localization of mNAT appeared to be basolateral and not
canalicular in the plasma membrane of hepatocytes surrounding
the central vein (Fig. 5b). There is a graded distribution of
mNAT expression from central vein to portal tract (Fig 5c).
There was no detectable expression of mNAT in endothelial cells
as revealed by confocal microscopy (Fig. 5 d and e). This specific
distribution of mNAT in hepatocytes is consistent with a func-
tion of this protein in amino acid transport (10).
Because human g17 shares more than 80% sequence homol-
ogy with mNAT, the amino acid transporting activities of this
gene were similarly analyzed and compared with those of mNAT.
Oocytes were injected with g17 or mNAT cRNAs, and, after 3
days, uptake rates of L-alanine, L-glutamine, L-glutamate, L-
histidine, and L-lysine were measured. Comparison between the
two groups demonstrated similar transport patterns (Fig 3f ).
Together, the results suggest that g17 is an N-system amino acid
transporter and, in fact, may be the human orthologue of mNAT.
In this report, we have identified mNAT as an N-system
transporter expressed predominantly in the liver. The liver is
known to contain four systems of transport for neutral amino
acids, A, ASC, N, and L (1, 6). Of these four, only the proteins
responsible for the ASC-transport system have been cloned and
further characterized as being pH-insensitive (29). The L-system
mainly transports bulky side chain-neutral amino acids and can
be trans-stimulated by substrate. However, this system is known
to be Na1-independent (4). Thus, the features of the above two
systems distinguish them from mNAT. System A functions as a
Na1-dependent transporter specific for small and N-methyl
group amino acids (30, 31). Although the A-system shares
similarities with mNAT in substrate selectivity, i.e., alanine, the
even stronger transport efficiency of mNAT for histidine and
glutamine matches the amino acid selectivity of the N-system. In
addition, in contrast to the A-system which shows trans-
inhibition, mNAT can be trans-stimulated by substrate (32). The
Km value of mNAT for L-glutamine (1.55 mM) determined from
the oocyte transport assay is similar to the value of 1.1 mM
obtained for the N-system by Kilberg et al. (27), despite the fact
that, in their study, the Km was derived from hepatocytes. The
selectivity of the mNAT amino acid transporter and its differ-
ential expression in liver indicates that this molecule may be
involved in urea and glutamine metabolism, a critical function of
hepatocytes, especially in physiology and pathophysiology in
which the gluconeogenic process is prominent. Taken together,
our data suggest that mNAT is an active N-system amino acid
transporter in the liver.
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